Microfluidics News Microfluidics News

  • Labcyte Reaches Agreement with Merck to Supply Acoustic-Mass Spectrometry Equipment
    on 17th April 2018 at 12:00 am

    Labcyte Inc. announced today that the company has entered an agreement with Merck, known as MSD outside the United States and Canada, to utilize Acoustic-Mass Spectrometry (Acoustic-MS) in drug discovery and development. Pioneered by Labcyte, acoustic droplet ejection (ADE) technology uses the gentle energy of sound waves to move liquids at nanoliter resolution with superior precision and accuracy. The technology does not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination, and enables miniaturization with reliable fluid transfers at volumes as low as 2.5 nanoliters. Labcyte has integrated its acoustic liquid handling technology with mass spectrometry in a process referred to as Acoustic-MS. Acoustic-MS has been shown to deliver high-quality data at extremely low volumes. As part of the agreement, prototype systems will be installed at select Merck sites where they will be evaluated within the context of existing and future workflows. “The ability for scientists to have full control over liquids with nanoliter resolution using our acoustic dispensing is forever changing broad areas of life sciences, from drug discovery to engineering biology,” said Mark Fischer-Colbrie, President and Chief Executive Officer at Labcyte. “Our continued effort to marry this novel capability with the power of mass spectrometry has created a new opportunity to achieve seminal advances driven by ultra-high throughput as well as exceedingly low costs and sample volumes. We look forward to working with Merck, a leading biopharmaceutical company, to build on the results achieved to date.” About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® liquid handling systems use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com […]

  • Dr. Sammy Datwani from Labcyte Inducted into the AIMBE College of Fellows
    on 9th April 2018 at 12:00 am

    Labcyte Inc. today announced that the American Institute for Medical and Biological Engineering (AIMBE) has inducted Sammy S. Datwani, Ph.D., Sr. Director, Principal Engineer, R&D at Labcyte to its College of Fellows. Dr. Datwani was nominated, reviewed, and elected by peers and members of the College of Fellows for contributions to leveraging microscale phenomena to enable label-free and high-throughput experimentation, screening and precision medicine. Election to the AIMBE College of Fellows is among the highest professional distinctions accorded to a medical and biological engineer. The College of Fellows is comprised of the top two percent of medical and biological engineers. College membership honors those who have made outstanding contributions to "engineering and medicine research, practice, or education” and to "the pioneering of new and developing fields of technology, making major advancements in traditional fields of medical and biological engineering, or developing/implementing innovative approaches to bioengineering education." Dr. Datwani joined Labcyte in 2007 and is responsible for leading internal research programs and managing the advanced developments for the creation of new products and capabilities for the company in the arena of acoustic droplet ejection. Dr. Datwani has over twenty years of experience directing, managing, inventing and applying cutting edge research and developments in both industry and academia. Prior to Labcyte, he was a Senior Scientist and the Advanced Technologies Group Manager at Eksigent Technologies, LLC. From 2000 – 2003, he held the position of R&D Engineer in the Advanced Technology Group at Caliper Life Sciences and spearheaded the development of several LabChip® devices. Dr. Datwani graduated with honors from The Johns Hopkins University with a B.S. in Chemical and Biomolecular Engineering. He holds a M.S. degree from The Columbia University in Chemical Engineering with a concentration in Polymer Science. He earned his Ph.D. in Chemical and Biomolecular Engineering from The Johns Hopkins University. Since 2011, Dr. Datwani has held an appointment as an Adjunct Professor in the Department of Biomedical, Chemical & Materials Engineering at San Jose State University. Labcyte Chief Executive Officer Mark Fischer-Colbrie commented: “Sammy’s knowledge, skill-set and leadership put him at the top of his field, and we are proud to have him as part of our team. Over the past decade he has made many notable contributions to advancing our acoustic dispensing technology and helped us attain leadership in our field. I warmly congratulate him on behalf of all of us at Labcyte.” A formal induction ceremony was held during the AIMBE Annual Meeting at the National Academy of Sciences in Washington, DC on April 9, 2018. Dr. Datwani was inducted along with 156 colleagues who make up the AIMBE College of Fellows Class of 2018. About AIMBE AIMBE is the authoritative voice and advocate for the value of medical and biological engineering to society. AIMBE’s mission is to recognize excellence, advance the public understanding, and accelerate medical and biological innovation. No other organization can bring together academic, industry, government, and scientific societies to form a highly influential community advancing medical and biological engineering. AIMBE’s mission drives advocacy initiatives into action on Capitol Hill and beyond. For more information about the AIMBE, please visit www.aimbe.org. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com PR Contact for AIMBE: Charlie Kim Director of Membership Services 202-496-9662 ckim@aimbe.org […]

  • Labcyte Acoustic Liquid Handlers Named Top Product in Lab Automation Conference Awards
    on 12th February 2018 at 12:00 am

    Labcyte Inc., was named the winner of two top awards at the International Conference of the Society for Laboratory Automation and Screening (SLAS), in recognition of the company's innovative acoustic liquid handlers. The company received a SLAS New Product Award for the Echo® 655T Liquid Handler, which was unveiled at the event along with the company's new Access™ Dual Robot System (DRS). The systems are key components of a new acoustic sample management solution that will support the next generation of pharmaceutical drug discovery which demands faster, high-throughput screens while consuming less sample. The company, along with its collaborators AstraZeneca, Brooks Life Sciences and Titian Software, introduced the new solution to attendees of SLAS2018 this week in San Diego. Labcyte also received the SelectScience® Reviewer's Choice Award for Drug Discovery & Development Product of the Year, based on thousands of product reviews written by scientists around the world on the scientific news and reviews site. The Echo 500 Series received strong marks for ease of use, service and value. According to one reviewer, the Echo Liquid Handler represents the "industry standard for touchless dispensing." Speaking at a press conference at the SLAS awards event, Labcyte CEO and President Mark Fischer-Colbrie said the acoustic droplet ejection technology pioneered by Labcyte, which uses the gentle energy of sound waves to move liquids at nanoliter resolution, was a "game changer" that has now become a mainstay of workflows across a wide range of application areas. Echo Liquid Handlers do not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination. The new Echo 655T system extends the benefits of contactless liquid transfer to the earliest stages of sample management to conserve sample material, preserve sample quality and deliver screening data of unparalleled quality, he said. Learn more about the new Access Dual Robot System and Echo 655T Liquid Handler. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com […]

  • Labcyte Introduces New Acoustic Sample Management Solution
    on 5th February 2018 at 12:00 am

    Labcyte Inc. today launched the Access™ Dual-Robot System (DRS) and the Echo® 655T Liquid Handler, key components of a new acoustic sample management solution that will support the next generation of pharmaceutical drug discovery as it demands faster, high-throughput screens while requiring less sample. The company, along with its collaborators AstraZeneca, Brooks Life Sciences and Titian Software, introduced the new solution to attendees of SLAS2018 this week in San Diego. Pioneered by Labcyte, acoustic droplet ejection (ADE) technology uses the gentle energy of sound waves to move liquids at nanoliter resolution with superior precision and accuracy. The technology does not contact the liquid in any way, avoiding the risk for sample loss, carryover or cross-contamination, and enables assay miniaturization with reliable fluid transfers at volumes as low as 2.5 nanoliters. The Echo 655T Liquid Handler makes it possible to use acoustically compatible tubes for high-density sample storage, extending the benefits of contactless liquid transfer to the earliest stages of sample management to conserve sample material and preserve sample quality. The complete solution includes automated storage systems that allow for rapid retrieval of new FluidX™ AcoustiX™ Sample Tubes, both supplied by Brooks Life Sciences. Racked tubes are then transferred to the Access DRS workstation where the Echo 655T Liquid Handler transfers samples directly from AcoustiX tubes into assay-ready plates for high-throughput screening applications. The Access DRS is a highly flexible and scalable platform for automating both tube- and plate-based acoustic liquid handling workflows. Orders for and results from samples processed on the system are managed by software developed by Titian Software. The combination of acoustic tubes and acoustic liquid handling was first developed in tandem with AstraZeneca to automate its pharmaceutical compound management system using fully acoustic workflows. By implementing this innovative technology, the research organizations of leading biopharmaceutical companies like AstraZeneca could greatly reduce the frequency at which samples are replaced and lower the costs of maintaining large sample collections. "Working with Labcyte, we have created a cutting-edge capability that will provide an unparalleled level of quality in the screening data produced from our biological assays, deliver new ways of working across all our research centers, reduce cost, and transform our ability to identify new molecules that could become medicines of the future," said Clive Green, Executive Director Sample Management at AstraZeneca's IMED Biotech Unit. "We are incredibly delighted to partner with AstraZeneca, Brooks and Titian to bring unprecedented efficiency and quality in sample management and screening to laboratories around the world," said Mark Fischer-Colbrie, President and Chief Executive Officer at Labcyte. "Our new sample management solution provides a smarter approach to high-throughput screening and sets new standards for sample integrity, efficiency and data quality, while at the same time reducing costs throughout the process." Labcyte will now be offering the system as part of its range of modular, customizable automation platforms. For more information about Labcyte activities at SLAS2018, including a series of tutorial workshops, visit www.labcyte.com/slas2018/. Attendees can also visit representatives of the company at booth 915 / 921. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com […]

  • Labcyte Launches New Family of Echo® Acoustic Liquid Handlers featuring 21 CFR Part 11 Compliance Software
    on 5th February 2018 at 12:00 am

    Labcyte Inc. today announced the release of a regulatory-ready family of Echo® Acoustic Liquid Handlers intended for pharmaceutical companies and laboratories developing and running bioassays. Integral to this new capability of Echo liquid handlers is new software, Echo® 21CFR11 Compliance Manager, and services designed to simplify deployment in regulated laboratories that must comply with the 21 CFR Part 11 regulations established by the U.S. Food and Drug Administration. Regulatory-ready versions of the Echo® 525, 550, and 555 Acoustic Liquid handlers are among several other new products the company introduced today at SLAS2018 in San Diego. Echo® 21CFR11 Compliance Manager, software included with the regulatory-ready systems, seamlessly integrates with Echo liquid handlers and Echo® software applications to control who can view, create, edit, approve, archive, and delete data that is generated by the systems. Using advanced proprietary verification algorithms, the software also detects any data tampering to give users confidence in the integrity of their data. "The new regulatory-ready Echo® Liquid Handlers make it easier for laboratories to successfully install, qualify and operate the system in a regulated laboratory environment," said Chris Grimley, Vice President of Marketing for Labcyte. "Echo 21CFR11 Compliance Manager software prevents unwanted changes to system settings or protocols and maintains full traceability of system use, which is critical for bioassay development and implementation." Acoustic liquid handling, pioneered by Labcyte, has been adopted across pharmaceutical sample management and screening programs for the dispensing of reagents in a wide variety of molecular and cellular assays. It uses the gentle energy of sound waves to move liquids in nanoliter increments with extremely high precision and accuracy. The technology is contactless, avoiding risks of sample carryover or cross-contamination and reduces sample volume needs, which in turn leads to improved data quality, higher throughput, and lower assay costs. For more information about the Echo 21CFR11 Compliance Manager, visit: www.labcyte.com/products/software/echo-compliance-manager. For more information about Labcyte activities at SLAS2018, including a series of tutorial workshops, visit www.labcyte.com/slas2018/. Attendees can also visit representatives of the company at booth 915-921. About Labcyte Inc. Labcyte, a global biotechnology tools company headquartered in San Jose, California, is revolutionizing liquid handling. Echo® Liquid Handlers use sound to precisely transfer liquids without contact, eliminating the use of pipettes. Labcyte instruments are used worldwide throughout the pharmaceutical and biotechnology industries, as well as by hospitals, service laboratories, contract research organizations, and academic institutions. Our customers work across a wide spectrum of scientific research, including drug discovery, genomics, proteomics, diagnostics, and personalized medicine. Labcyte has 62 U.S. patents and others internationally. For more information, visit www.labcyte.com. PR Contact: Nicole Litchfield Bioscribe, Inc. 415-793-6468 nicole@bioscribe.com […]